180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 148.1% in December

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 160,800 shares, a growth of 148.1% from the November 30th total of 64,800 shares. Based on an average daily volume of 2,230,000 shares, the short-interest ratio is currently 0.1 days. Approximately 31.4% of the company’s stock are short sold.

180 Life Sciences Trading Down 24.0 %

180 Life Sciences stock opened at $2.15 on Friday. 180 Life Sciences has a 52 week low of $1.16 and a 52 week high of $17.75. The stock has a 50 day moving average of $2.76 and a 200-day moving average of $2.23.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.